Spark Therapeutics, Inc.

Spark Therapeutics, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Roche Holding AG, which influences its climate commitments and emissions reporting.

As part of its corporate family relationship, Spark Therapeutics inherits emissions data and reduction initiatives from Roche Holding AG. However, no specific reduction targets or achievements have been outlined for Spark Therapeutics itself. The absence of documented reduction targets suggests that the company may be aligning its climate strategies with those of its parent organisation.

Roche Holding AG has established various climate initiatives, including commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). These initiatives aim to drive significant reductions in greenhouse gas emissions across their operations, although specific figures for Spark Therapeutics are not disclosed.

In summary, while Spark Therapeutics is part of a larger corporate structure with climate commitments, it currently lacks specific emissions data and reduction targets. The company's climate strategy appears to be influenced by its parent company, Roche Holding AG, which is actively engaged in sustainability efforts.